Immunoglobulins
CSL Biotherapies manufactures a range of products under a National Blood Authority supply agreement, including intravenous immunoglobulin, normal immunoglobulin, Anti-D and specific immunoglobulins (eg, CMV, hepatitis B, tetanus).
Plasma-derived products manufactured by CSL include the following immunoglobulins:
► Hepatitis B immunoglobulin-VF
Prescription of these products often requires specific specialist consultation. Always read and refer to the product information sheet of every product prior to the administration.
|
|
|
CMV Immunoglobulin-VF |
CMV immunoglobulin-VF
CMV immunoglobulin-VF is used to prevent CMV infection in bone marrow, renal, cardiac and liver transplant recipients who are CMV antibody negative where the donor is CMV antibody positive.
It is also used for the treatment of established CMV infection (eg, CMV pneumonia, renal parenchymal infection) in association with virucidal treatment (eg, ganciclovir).
| Title: | |
| Authors: | Dr Elizabeth Campbell and Dr Joanne Pink |
| Description: | Information from CSL Biotherapies and the Australian Red Cross Blood Service about CMV immunoglobulin-VF shelf-life extension from 12 to 24 months and resultant packaging changes. |
| Date modified: | 14 November 2011 |
440 KB
CMV immunoglobulin-VF product information [on www.csl.com.au]
This link takes you to CSL's web information about CMV immunoglobulin. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of CMV immunoglobulin-VF.
|
|
|
Hepatitis B immunoglobulin-VF |
Hepatitis B immunoglobulin-VF
Hepatitis B immunoglobulin-VF is administered intramuscularly and indicated for the prevention of hepatitis B infection from developing in a person who has been exposed to the hepatitis B virus, who has not received prior vaccination, or whose vaccination program is incomplete. This is availabe in 100 IU or 400 IU vials.
This is also indicated for those whose antibody level is inadequate. In addition, Hepatitis B immunoglobulin helps prevent hepatitis B infection in infants born to mothers with hepatitis B.
Hepatitis B immunoglobulin-VF product information [on www.csl.com.au]
This link takes you to CSL's web information about Hepatitis B immunoglobulin. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of Hepatitis B immunoglobulin-VF.
|
|
|
Normal immunoglobulin-VF |
Normal immunoglobulin-VF
Normal immunoglobulin-VF is indicated in primary and secondary hypogammaglobulinaemia. It is also used in patients who are susceptible contacts of hepatitis A, measles and poliomyelitis.
Normal immunoglobulin-VF product information [on www.csl.com.au]
This link takes you to CSL's web information about Normal immunoglobulin. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of Normal immunoglobulin-VF.
|
|
|
Rh(D) immunoglobulin-VF |
Rh(D) immunoglobulin-VF
Rh(D) immunoglobulin-VF (Anti-D) is given as prophylaxis to Rh(D)-negative women during pregnancy and following birth of an Rh(D)-positive baby to help prevent Haemolytic Disease of the Newborn.
It should be given preferably within 72 hours of a sensitizing event. It is available in 250 IU and 625 IU vials.
If an intravenous (IV) preparation is required, Rhophylac® is available, which can be used either intramuscularly or intravenously. Rhophylac is manufactured from imported plasma.
The Guidelines on the prophylactic use of Rh(D) Immunoglobulin (Anti-D) in obstetrics details the appropriate use and indications of this product.
You can order or download a range of educational support materials available on the latest guidelines for the use of Rh(D) immunoglobulin (Anti-D).
| Title: |
Rh(D) Immunoglobulin-VF |
| Authors: | Dr Elizabeth Campbell and Dr Joanne Pink |
| Description: | Information from CSL Biotherapies and the Australian Red Cross Blood Service about Rh(D) Immunoglobulin-VF. |
| Date modified: | 17 November 2011 |
Rh(D) immunoglobulin-VF (Anti-D) product information [on www.csl.com.au]
This link takes you to CSL's web information about Rh(D) immunoglobulin. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of Rh(D) immunoglobulin-VF.
|
|
|
Rhophylac® |
Rhophylac®
Rhophylac® is indicated for use in large fetomaternal haemorrhage (FMH) where administration of intramuscular Rh(D) immunoglobulin is either contraindicated or not practical, or for inadvertent or emergency transfusion of Rh(D) positive blood to an Rh(D) negative female of childbearing potential.
Rhophylac®, manufactured by CSL Behring, replaces WinRHO-SDF as the Rh(D) immunoglobulin for intravenous use available within Australia.
Rhophylac® frequently asked questions 209 KB
Rhophylac® product information [on www.csl.com.au]
This link takes you to CSL's web information about Rhophylac®. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of Rhophylac®.
Tetanus immunoglobulin-VF
|
|
|
Tetanus immunoglobulin-VF IM |
Intramuscular
Tetanus immunoglobulin-VF – intramuscular is used for passive protection of individuals who have sustained a tetanus-prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful.
This is also given to fully immunised individuals with a tetanus prone wound if more than 10 years have elapsed since the last dose of toxoid or vaccine. A vaccination regime should be initiated at the same time.
Tetanus immunoglobulin-VF – intramuscular product information [on www.csl.com.au]
This link takes you to CSL's web information about Tetanus immunoglobulin-VF (IM). You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of Tetanus immunoglobulin.
Intravenous
Tetanus immunoglobulin-VF – intravenous is issued for management of clinical tetanus. A vaccination regime should be initiated at the same time.
Tetanus immunoglobulin-VF – intravenous product information [on www.csl.com.au]
This link takes you to CSL's web information about Tetanus immunoglobulin. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of Tetanus immunoglobulin.
|
|
|
Zoster immunoglobulin-VF |
Zoster immunoglobulin-VF
Zoster immunoglobulin-VF is indicated for prophylaxis against varicella in patients who meet the following criteria: neoplastic disease (leukaemia or lymphoma), congenital or acquired immunodeficiency, undergoing immunosuppressive therapy with steroids or antimetabolites, negative or unknown prior history of chickenpox.
This should be administered within 96 hours of exposure. It is not indicated for prophylaxis in immunodeficient children or adults when there is a prior history of varicella, unless the immunosuppressed status is associated with bone marrow transplantation.
Zoster immunoglobulin-VF product information [on www.csl.com.au]
This link takes you to CSL's web information about Zoster immunoglobulin. You can download the product information (PI) sheet from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, adverse effects, and dosage & administration of Zoster immunoglobulin-VF.
